Abstract
Tumor infiltrating lymphocytes (TIL) play an essential role in mediating response to chemotherapy and improving clinical outcomes in all subtypes of breast cancer. Triple negative breast cancers (TN) are most...
Highlights
Infiltration of immune cells, infiltration of anti-tumor type 1 lymphocytes, has predicted improved prognosis in many different tumor types including colon, ovarian, lung and breast cancer [1,2,3,4]
Recent evidence has emerged that tumor infiltrating lymphocytes (TILs) present in breast cancer prior to treatment can predict response to therapy and improved prognosis [4, 5]
In the FINHER study of 209 HER2 breast cancer patients, only patients that had been treated with trastuzumab had improved distant disease free survival (DFS) with each 10 % increase in TIL (HR 0.82 95 % CI 0.58 to 1.16, p = 0.025 n = 94) [19]
Summary
Infiltration of immune cells, infiltration of anti-tumor type 1 lymphocytes, has predicted improved prognosis in many different tumor types including colon, ovarian, lung and breast cancer [1,2,3,4]. Recent evidence has emerged that tumor infiltrating lymphocytes (TILs) present in breast cancer prior to treatment can predict response to therapy and improved prognosis [4, 5].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
